【作者】 毋永娟； 丁晓岭； 张丽；

【Author】 BaoTou cancer Hospital014030 BaoTou medicine college library 014030

【机构】 包头市肿瘤医院； 包头市医学院图书馆；

【摘要】 目的:探讨支气管动脉灌注细胞周期非特异性药物联合外周静脉持续化疗,静点细胞周期特异性药物治疗Ⅲ期以上肺癌临床疗效和毒副反应。方法:对84例Ⅲ期以上肺癌随机分为治疗组42例,对照组42例。治疗组以支气管动脉灌注+外周静脉持续化疗,a、小细胞肺癌支气管动脉灌注 DDP80-120mg或CBP 300-400mg／次或CTX 0．8- 1．0／次,12小时后外周静点滴V-P16 100mg／m2d1-5或V- m26100g／m2d1-3或HCPT10mgd1-5。b、非小细胞肺癌支气管动脉灌注E—ADM 80mg／m2、MMC 4mg／m2、DDP 1 00 mg／m2,12小时后外周静脉持续点滴5-Fu0．5／m2d1-5或 NVB40mg／m2d1,8或VDS3mg／m2d1-8,对照组42例小细胞肺癌以CE方案为主,非小细胞肺癌以MVP或NP方案为主,全组治疗均在3个周期以上,可评价疗效。结果:近期客观疗效:治疗组42例,CR+PR32例,总有效率76．1％,对照组CR+PR17例,总有效率40．4％。两组近期疗效比较有非常显著差异(P<0．01),治疗组中位缓解期6．5个月,对照组中位缓解期4．2个月,两组比较有显著差异(P<0．05)。远期疗效:治疗组中位生存14．6个月,对照组中位生存11．5个月,有显著性差异(P<0．05),化疗毒副反应两组无差异。结论:按照细胞周期动力学作用,将细胞周期非特异性药物进行BAI联合细胞周期特异性药物外周静脉化疗,治疗中晚期肺癌,可以提高疗效及中位生存期,未增长毒副反应,利于临床推广使用。更多还原

【Abstract】 Objective: To observe the clinical effect and toxic effect of in grade advanced lung cancer treated by broncho arterial infusing plus peripheral vein continuous chemotherapy. Methods: eighty four case III grade lung cancer were divided randomly into therapeutic group (n=42) and control group (n=42), the therapeutic group treated with broncho arterial infusing plus peripheral vein continuous chemotherapy. The regimen were small lung cancer treated with broncho arterial infusing DDP 80-120mg or CBP 300-400mg, or CTX 0.8-1.0, after twelve hour give continuous chemotherapy with VP16 100mg/m2 d1-5, or Vm26 100mg/m2 d1-3 or HCPT 10mg d1-5, no small lung cancer broncho arterial infusing EIP-ADM 80mg/m2, MMC 4mg/m2, DDP 100mg/m2, after twelve hour give continuous chemotherapy with S-Fu 0.5/m2 d1-5 or NVB 40mg/m2 d1,8 or NVB 40mg/m2 d1,8. Or VDS 3mg/ m2 d1,8. In the same time, the control group which were treated by small lung cancer CE regimen, no small lung cancer with MVP or NP. All chemotherapy with three cycles, and evaluation. Results: The therapeutic group were 42 cases, CR+PR 32 cases, the response rate was 76. 1%, the control group were CR+PR 17 cases, the all response rate was 40.4%. the therapeutic group was obvious difference than the control group (P<0.01). the moderate effective time 6.5 month, the control group was 4.2 month, Two group was difference (P<0.05). the median survival was 14.6 month in the therapeutic group. The control group was the median survival 11.5 month, the two group was obvious difference than the control group (P<0.05). the toxic effect no difference. Conclusion: the broncho arterial infusing plus peripheral vein continuous chemotherapy throated advanced lung cancer, as described here, is a well-tolerated regimen with acceptable toxicity, more effective treatment schemes are required to improve disease control and overall survival.更多还原